International Journal of Pharmaceutical Compounding

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2018 Pg. 263	Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension Author(s):
May/Jun 2010 Pg. 246	Lansoprazole 3-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2022 Pg. 429	Lansoprazole 3-mg/mL in Ora-Blend Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2025 Pg. 46	Lansoprazole 3-mg/mL Oral Suspension Author(s):
Jan/Feb 2007 Pg. 74	Lansoprazole 3-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Nov/Dec 2004 Pg. 462-465	Basics of Compounding for Cough Author(s): Allen Loyd V Jr
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Mar/Apr 2011 Pg. 175	Erratum: Stability of Venlafaxine Immediate-Release Suspensions Author(s): Allen Loyd V Jr
Jul/Aug 2001 Pg. 314-319	Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration Author(s): Trissel Lawrence A, Saenz Christopher, Williams Kimberly Y, Ingram Delshalonda S
Jul/Aug 2019 Pg. 351	Erratum: Zur E. Topical Treatment of Primary Focal Hyperhidrosis, Part 2. IJPC 2019; 23(2):94-104. Author(s):
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
Jan/Feb 2001 Pg. 9-12	Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients Author(s): Schotik Debora
May/Jun 2003 Pg. 233-239	Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Author(s): Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
Sep/Oct 2023 Pg. 420	Nitazoxanide 20-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2007 Pg. 17-19	Pediatric Oral Formulations: A Continual Challenge Author(s): Hurtado Josephine, Moffett Brady S
Jan/Feb 2021 Pg. 43	Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2017 Pg. 105-108	Restructuring the Art of Health by Pharmacists: Formulation Designs with Oral Vehicles--Teaching Pharmacy Students Author(s): Benischek Rita
Sep/Oct 2015 Pg. 407	Nimodipine 3-mg/mL Oral Solution Author(s): Allen Loyd V Jr
Mar/Apr 2006 Pg. 82	Erratum: Allen LV Jr. Lidocaine hydrochloride 2%, misoprostol 0.0024%, and phenytoin 2% topical wound powder. IJPC 2004; 8(4): 298 Author(s): Allen Loyd V Jr
Sep/Oct 2005 Pg. 402-406	Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations Author(s): Sidhom Madiha B, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L

Abstract

Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension

Page(s): 263

Abstract

Related Keywords

Related Categories

Related Articles from IJPC